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Crohn’s disease (CD) results from dysregulated immune responses to gut microbiota in genetically susceptible individuals, aﬀecting
multiple areas of the gastrointestinal tract. Innate lymphoid cells (ILCs) are tissue-resident innate eﬀector lymphocytes which play
crucial roles in mucosal immune defense, tissue repair, and maintenance of homeostasis. The accumulation of IFN-γ-producing
ILC1s and increased level of proinﬂammatory cytokines produced by ILCs has been observed in the inﬂamed terminal ileum of
CD patients. To date, the precise mechanisms of ILC plasticity and gene regulatory pathways in ILCs remain unclear. Signal
transducer and activator of transcription 3 (STAT3) regulates gene expression in a cell-speciﬁc, cytokine-dependent manner,
involving multiple immune responses. This study proposes the positive correlation between the prevalence of STAT3 rs744166
risky allele “A” with the severity of disease in a cohort of 94 CD patients. In addition, the results suggest an increased STAT3
activity in the inﬂamed ileum of CD patients, compared to unaﬀected ileum sections. Notably, IL-23 triggers the diﬀerentiation
of CD117+NKp44- ILC3s and induces the activation of STAT3 in both CD117+NKp44- and CD117-NKp44- ILC subsets,
implying the involvement of STAT3 in the initiation of ILC plasticity. Moreover, carriage of STAT3 “A” risk allele
exhibited a higher basal level of STAT3 tyrosine phosphorylation, and an increased IL-23 triggered the pSTAT3 level. We
also demonstrated that there was no delayed dephosphorylation of STAT3 in ILCs of both A/A and G/G donors. Overall,
the results of this study suggest that IL-23-induced activation of STAT3 in the CD117-NKp44- ILC1s involves in ILC1-to-
ILC3 plasticity and a potential regulatory role of ILC1 function. Those genetically susceptible individuals carried STAT3
rs744166 risky allele appear to have higher basal and cytokine-stimulated activation of STAT3 signal, leading to prolonged
inﬂammation and chronic relapse.
1. Introduction
Crohn’s disease (CD) is one type of inﬂammatory bowel
disease (IBD) that involves a chronic relapsing inﬂammation
of the gastrointestinal tract, causing abdominal pain and
diarrhea and can eventually lead to severe strictures or ﬁstu-
lae which enhance the need for surgical intervention [1]. The
pathogenesis of CD involves a complex interaction between
genetic factors, environmental factors, and dysregulated
immune responses [2]. To date, the precise mechanisms
behind the disease initiation and progression remain unclear.
However, it is widely accepted that CD involves an inappro-
priate and continuing mucosal inﬂammatory immune
response to intestinal microﬂora in genetically susceptible
individuals [3, 4]. Historically, the dysfunctional adaptive
immune responses were investigated in terms of Th1/Th17
responses in CD patients, and results suggested that T cells
are responsible for the increased production of proinﬂamma-
tory cytokines, such as IFN-γ and IL-17A [5]. Recently,
increasing evidence suggests that innate immunity also plays
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a signiﬁcant role in the pathogenesis of CD [6, 7]. Innate lym-
phoid cells (ILCs) have been identiﬁed as innate eﬀector cells
that are involved in bacterial defense, induction of inﬂamma-
tion, and the maintenance of homeostasis [8]. The nomen-
clature of ILCs is based on their signature cytokines and the
transcriptional factors that regulate their diﬀerentiation.
They are classiﬁed into natural killer (NK) cells, group 1 ILCs
(ILC1s), group 2 ILCs (ILC2s), group 3 ILCs (ILC3s), and
lymphoid tissue inducer (LTi) cells [9]. In contrast to T cells,
ILCs lack antigen-speciﬁc receptors and are constitutively
located in barrier tissues, responding to alarmins as well as
cytokine signals released following tissue damage or mucosal
infection [10, 11]. As tissue-resident innate compartments of
T helper cells, ILCs undergo transdiﬀerentiation, also known
as plasticity, in response to cytokine cues in the surrounding
tissue microenvironment [12]. Speciﬁcally, in Crohn’s
disease patients, we and other researchers have identiﬁed
the accumulation of IFN-γ-producing ILC1s at the expense
of IL-17/IL-22-producing ILC3s in the inﬂamed intestinal
tissues of Crohn’s disease patients, implying this ILC3-to-
ILC1 plasticity may be involved in the CD pathogenesis
[13, 14]. Moreover, researchers have identiﬁed that the diﬀer-
entiation toward ILC1s was driven by IL-12, and conversely,
IL-23 promoted polarization toward ILC3s in vitro and
in vivo [15]. Notably, IL-23 responsive ILCs have been
recently recognized as the important cell population that
associates with the pathogenesis of colitis in several murine
models [16].
Genome-wide association studies (GWAS) have identi-
ﬁed 170 disease susceptibility gene loci that are associated
with Crohn’s disease [17]. In 2014, a meta-analysis indicated
that the STAT3 rs744166 polymorphism was highly associ-
ated with CD susceptibility, especially among Caucasians
[18]. Additionally, the STAT3 rs744166 risk allele “A” has
been associated with increased cellular STAT3 activation in
leukocytes in pediatric Crohn’s disease patients [19]. Signal
transducer and activator of transcription 3 (STAT3) is a cru-
cial transcription factor which regulates cells associated with
both innate and adaptive mucosal immunity in a cell-speciﬁc,
cytokine-dependent manner [20]. Particularly, STAT3 plays
a central role in Th17 commitment through its direct regula-
tion of RORγt and regulates Th17-cytokine production in
response to IL-23 [21]. In addition, it has been shown that
STAT3 is essential for ILC3s to produce IL-22 against intes-
tinal infection in mice [22, 23]. Recent improvements in
genetic analysis in human studies have revealed the distinct
gene regulatory mechanisms in adaptive and innate lym-
phoid cells [24, 25]. Although ILC3s are the innate analog
of Th17 cells, the exact regulation of STAT3 in ILC3 develop-
ment and plasticity remains unclear. In this study, we inves-
tigate the role of STAT3 in the pathogenesis and progression
of Crohn’s disease, and more speciﬁcally, we examine the
STAT3 signaling involving in innate lymphoid cell plasticity.
2. Materials and Methods
2.1. Human Intestinal Lamina Propria Mononuclear Cell
(LPMC) Isolation. All the surgical resections of the terminal
ileum from Crohn’s disease patients were obtained from
UF Health Shands Hospital, following an approved
IRB#201500440. LPMCs were isolated by epithelial elimi-
nation and enzyme digestion. Brieﬂy, the surgical resec-
tions were cut into 1-2 mm pieces after removal of the
outer fat tissue and muscle layer. The epithelial layer was
removed by 1X Hanks’ Balanced Salt Solution (HBSS)
with phenol red and glucose, no calcium, and no magne-
sium, containing 2% FBS (Gibco®), 100 U/ml penicillin,
100 μg/ml streptomycin, 25 μg/ml gentamycin, and 0.5
mM DTT. Tissues were then digested with 1X HBSS con-
taining 1% FBS (Gibco®), 100 U/ml collagenase XI
(Roche), 20 μg/ml Dispase neutral protease II (Roche),
and 10 μg/ml deoxyribonuclease I (StemCell Technolo-
gies). The remaining tissues were mechanically dissociated
and were passed through 70 μm cell strainers (Corning®).
All cells were then slowly cryopreserved in CryoStor®
CS10 (StemCell Technologies) and transferred into liquid
nitrogen for future use.
2.2. Human Peripheral Blood Mononuclear Cell (PBMC)
Isolation. Donor blood was purchased from LifeSouth
Community Blood Center, and patient blood was obtained
from UF Health Shands Hospital, following an approved
IRB#201500440. PBMCs were isolated by gradient centrifu-
gation. Brieﬂy, whole blood samples were diluted 1 : 1 ratio
with 1XPBS containing 2% FBS. Diluted blood samples were
carefully transferred into SepMate™-50 tubes containing 15
ml of Lymphoprep™ (StemCell Technologies). Samples were
then centrifuged at 1,200xg for 10 mins, and the cell suspen-
sions above the insert in SepMate™-50 tubes were transferred
into new 50 ml conical tubes. PBMCs were collected by
centrifuging at 300xg for 8 mins. All cells were then slowly
cryopreserved in CryoStor® CS10 (StemCell Technologies)
and transferred into liquid nitrogen for future use.
2.3. Genotyping of STAT3 rs744166. Genomic DNA was
extracted from whole blood using the Gentra Puregene Kit
(QIAGEN). Patients were genotyped for the STAT3
rs744166 (assay ID: C___3140282_10, Cat. No. 4351379,
TaqMan) single nucleotide polymorphism (SNP) using the
TaqMan system, running on the QuantStudio 7 Flex Real-
Time PCR System (Applied Biosystems).
2.4. Quantitative RT-PCR. Total RNA was isolated from
intestinal tissues of Crohn’s disease patients using QIAzol
Lysis Reagent (QIAGEN) or from whole blood of CD
patients using the RNeasy Kit (QIAGEN). A two-step RT-
PCR was performed using the SuperScript® VILO cDNA
Synthesis Kit (Thermo Fisher Scientiﬁc) for reverse tran-
scription (RT), and PCR was done using the QuantStudio 7
Table 1: STAT3 rs744166 genotyping in a cohort of Crohn’s disease
patients.
Genotype Number Frequency
GG 12 12.8%
GA 41 43.6%
AA 41 43.6%
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Flex Real-Time PCR System (Applied Biosystems). The PCR
was performed using a 20 μl reaction volume containing the
cDNA, 2× TaqMan® Gene Expression Master Mix, nuclease-
free water, and 1× TaqMan Gene Expression Assay for
STAT3 (Thermo Fisher Scientiﬁc). The housekeeping gene
GAPDH was used as an endogenous control to normalize
target gene expression levels. 2^-ΔΔCt value was calculated
and used to represent the gene expression fold change.
2.5. Immunohistochemistry. The immunohistochemistry
staining followed the manufacturer’s protocols, and the
heat-induced epitope retrieval method with citrate buﬀer
was used for antigen retrieval. Primary antibodies, speciﬁ-
cally anti-STAT3 (Y705) antibody (rabbit polyclonal,
ab214465 (dilution 1:500), Abcam), were added and incu-
bated at 4°C overnight. The primary antibodies were detected
using a mouse and rabbit speciﬁc HRP/DAB IHC detection
kit (ab236466, Abcam) following the manufacturer’s
instructions.
2.6. Flow Cytometry. Single-cell suspensions isolated from
intestinal tissues of CD patients were stained with FITC-
conjugated anti-human lineage cocktail 3 (Lin3) (CD3,
CD14, CD19, and CD20; clone: MφP9, L27, SK7, and
SJ25C1; BD Biosciences), PerCP-conjugated anti-human
CD45 (clone: HI30, BioLegend), APC-conjugated anti-
human CD127 (clone: A019D5, BioLegend), PE-conjugated
anti-human NKp44 (clone: P44-8, BioLegend), PE-Cy7-
conjugated anti-human CD117 (clone: 104D2, eBioscience),
Brilliant Violet 421-conjugated anti-human CRTH2 (clone:
BM16, BioLegend), and Alexa Fluor 647-conjugated anti-
STAT3 Phospho-Tyr705 (clone: 13A3-1, BioLegend). Viabil-
ity was assessed by Fixable Yellow Dead Cell Stain (Thermo
Fisher Scientiﬁc). For phosphoﬂow staining, cells were stim-
ulated with 20 ng/ml of recombinant human IL-23 (carrier
free, R&D) for 15 mins and were permeabilized by True-
Phos™ Perm Buﬀer (BioLegend) following the manufac-
turer’s protocol. AbC™ Total Antibody Compensation Beads
(Cat. No. A10497, Life Technologies) and ArC™ Amine
Reactive Compensation Beads (Cat. No. A10346, Life Tech-
nologies) were used for compensation. Data were acquired
on an LSRFortessa™ ﬂow cytometer (BD Biosciences) using
BD FACSDiva™ software in the Cytometry Core at the Uni-
versity of Florida and analyzed by FlowJo software (Version
10, Tree Star Inc.).
2.7. Histology. The surgical tissues containing the structures
of mucosa, submucosa, and muscular layer were ﬁxed in
10% neutral-buﬀered formalin (Fisher Scientiﬁc) for at least
18 hrs. The ﬁxed tissues were then embedded in paraﬃn, sec-
tioned, and stained with hematoxylin and eosin.
2.8. Gene Expression Heatmap. Total RNA was isolated from
intestinal tissues of Crohn’s disease patients using QIAzol
Lysis Reagent (QIAGEN), and a two-step RT-PCR was per-
formed using the SuperScript® VILO cDNA Synthesis Kit
(Thermo Fisher Scientiﬁc) for reverse transcription (RT).
Quantitative RT-PCR was done using TaqMan® Gene
Expression Array Plates (96-well Standard Human Immune
Response Array, Cat. No. 4414073, TaqMan) on the Quant-
Studio 7 Flex Real-Time PCR System (Applied Biosystems).
The expression levels of each gene were calculated using the
2^-ΔΔCt value, and GAPDH was used as endogenous con-
trol gene whereas normal unaﬀected tissue sample was used
as reference control. Heatmap of RT-PCR data was generated
using R programming.
2.9. Statistical Analysis. The correlation of surgery number
and STAT3 rs744166 risk allele was tested by a GENMOD
procedure in SAS with the adjustment of age at diagnosis.
Statistical analysis was performed using GraphPad Prism 6
software (GraphPad Software, CA), and all comparisons
between experimental groups were evaluated by the unpaired
Mann-Whitney t test. Diﬀerences with a value of p < 0 05
were considered as signiﬁcant and were indicated by an
asterisk.
3. Results
3.1. STAT3 rs744166 Risk Allele “A” Carriage Positively
Correlates with Clinical Outcomes of Crohn’s Disease
Patients. Surgery is not commonly required for CD patients;
however, depending on disease severity and chronic
relapse of inﬂammation, surgical removal of the inﬂamed
tissues is needed in certain cases. Even though the carriage
of STAT3 rs744166 risk “A” allele is relatively high in
healthy individuals, which is 56.4% compared to 63.6%
carriage in CD patients [26], it has been indicated in sev-
eral studies that STAT3 rs744166 is associated with
Crohn’s disease susceptibility [18, 27]. Herein, we ﬁrst
genotyped our cohort of 94 CD patients and found that
87.2% of this cohort carried STAT3 rs744166 risk allele
“A,” heterozygous or homozygous (Table 1). In order to
Table 2: Surgery numbers in risky allele carrier and nonrisky allele carrier among the cohort of Crohn’s disease patients.
Genotype
Surgery numbers
Total
0 1 2 3 4 5 6
GG
Number 9 3 0 0 0 0 0 12
Percentage 9.57% 3.19% 0% 0% 0% 0% 0% 12.77%
AA+GA
Number 26 21 11 9 8 6 1 82
Percentage 27.66% 22.34% 11.70% 9.57% 8.57% 6.38% 1.06% 87.23%
Total
Number 35 24 11 9 8 6 1 94
Percentage 37.23% 25.53% 11.70% 9.57% 8.51% 6.38% 1.06% 100%
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investigate whether this STAT3 single nucleotide polymor-
phism (SNP) was associated with clinical outcomes (Sup-
plementary Table 1), we used the number of surgeries
that these patients received after diagnosis to represent
disease severity (Table 2). We observed that more than
60% of patients do not respond well to drug treatment
and eventually need surgery. Moreover, 37.22% of patients
have received multiple surgeries (surgery numbers ≥2). In
addition, 57.45% of patients have strictures located in var-
ious sites, and 48.94% of patients suﬀered from ﬁstula at
diﬀerent locations (Figures 1(a) and 1(b)). However, there
is no correlation between STAT3 rs744166 and the pres-
ence of stricture or ﬁstula. Furthermore, a statistical corre-
lation test of numbers of surgeries and the SNP was
performed, and we found that there was a positive corre-
lation between STAT3 rs744166 risky allele carriage (G/A
or A/A) and surgery numbers (Figure 1(c)). Taken
together, these results implied a potential involvement of
dysfunctional STAT3 activity in the chronic relapse of
Crohn’s disease patients.
5.32% anal
8.51% colon
1.06% duodenum
1.06% ileocecal
35.11% ileum
1.06% ileum+anus
2.13% ileum+colon
2.13% ileum+jejunum
1.06% jejunum
42.55% none
Location of stricture
Total = 94
(a)
1.06% anal 14.89% perianal
1.06% colon 1.06% perianal+ileum
1.06% colovaginal 2.13% perianal+ileum+colon
2.13% duodenal+colon 4.26% perianal+rectum
8.51% ileum 1.06% perirectal
1.06% ileum+colon 6.38% rectum
1.06% ileum+rectum 2.13% rectum+perianal
1.06% ileum+rectum+perianal 51.06% none
Location of fistula
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Figure 1: STAT3 rs744166 risky allele “A” positively correlates with surgery numbers in Crohn’s disease patients. Patients in this study suﬀered
stricture and ﬁstula at various sites of the gastrointestinal tract. The locations of strictures was shown in (a), and (b) demonstrated various
locations of ﬁstula in this cohort of patients. (c) The correlation of surgery numbers and carriage of risky allele “A” was tested by a
GENMOD procedure in SAS with the adjustment of age of diagnosis. Diﬀerent surgery numbers were represented as diﬀerent colors.
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3.2. Increased stat3 and Its Target Gene Expression in the
Inﬂamed Ileum of Crohn’s Disease Patients. To further inves-
tigate STAT3 activity in the disease state, we evaluated stat3
mRNA levels in the inﬂamed ileum tissues from CD patients
who received more than 2 surgeries. Based on distinct histo-
logical features, for instance, ulceration, crypt abscesses, lym-
phoid aggregates, and architectural distortion, we deﬁned
surgical resections from CD patients as microscopic unaf-
fected ileum and inﬂamed ileum (Figure 2(a)). We observed
a signiﬁcantly increased level of stat3 mRNA expression in
the inﬂamed ileums, compared to unaﬀected ileum of CD
patients (Figure 2(b)), suggesting STAT3 activity was upreg-
ulated under inﬂammation. In addition, the stat3 expression
level was also increased in the peripheral blood of CD
patients, compared to healthy donors (Supplementary
Figure 1). Furthermore, an altered expression pattern of
inﬂammatory genes was observed in the inﬂamed ileum of
CD patients, compared to unaﬀected ileum (Figure 2(c), A).
Among those inﬂammatory genes, we further evaluated the
STAT3-related genes, such as Il-17a, tnf, and Il-10, and
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Figure 2: Increased STAT3 target gene expression and stat3 mRNA expression in the inﬂamed ileum of Crohn’s disease patients. (a)
Representative H&E staining illustrates histological appearance in unaﬀected and inﬂamed terminal ileum of CD patients. Compared
to unaﬀected ileum, the inﬂamed ileum showed distinct histological signs of inﬂammation, including increased inﬁltration of
immune cells in the lamina propria, loss of intact small intestinal architecture, and ulceration. Images were obtained under 20x
magniﬁcation. Scale bar = 50μm. (b) stat3 mRNA expression was upregulated in the inﬂamed ileum of CD patients (n = 10), compared to
unaﬀected ileum tissues (n = 5). The gene expression fold change was calculated as 2^-ΔΔCt value, using GAPDH as endogenous control.
Statistical analysis was done by the unpaired Mann-Whitney t test, α = 0 05. (c) Altered expression pattern of inﬂammatory genes in the
inﬂamed tissues of CD patients. Among these genes, an increased STAT3-related gene expression was observed in the inﬂamed ileum of
CD patients. GAPDH was used as endogenous control.
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found increased expression levels of those STAT3 target
genes in inﬂamed ileum tissues (Figure 2(c), B). The
evaluated gene IDs were listed in Supplementary Table 2,
and the calculated expression levels of each gene were
reported in Supplementary Table 3. In order to investigate
whether STAT3 rs744166 associates with the increase of
STAT3-related gene expression during inﬂammation, we
then genotyped these patients. As the result, the genotype
of sample 1, 2, and 5 was A/A, and the genotype of sample
6 was GG. Samples 3 and 4 were the same individual before
and after treatment of 5-month Ustekinumab (anti-IL12/23
p40 antibody), and this patient was a heterozygous “A”
carrier. However, the data implied this increased
proinﬂammatory gene expression level was not associated
with STAT3 rs744166 risk allele “A” but correlated with the
inﬂammation level.
3.3. Increased Activation of STAT3 Signaling in the Inﬂamed
Ileum of Crohn’s Disease Patients. To examine the activation
of STAT3 signaling, we performed IHC staining of pSTAT3-
Y705 on paraﬃn-embedded tissue sections of CD patients.
The phosphorylated STAT3 signal was detected mainly in
those immune cells located in the lamina propria, as well as
intestinal epithelial cells for tissue repair in the inﬂamed
ileum [28] (Figure 3(a)). pSTAT3+ cells were counted per
high-power ﬁeld (HPF) in unaﬀected tissues and inﬂamed
tissues of CD patients, and an increased activation of STAT3
was observed in the inﬂamed ileum (Figure 3(b)).
3.4. Activation of STAT3 Signaling in Innate Lymphoid Cells.
STAT3 has been shown that plays a critical role in Th17
development and function, responding to IL-6 and IL-23 sig-
nals. As the innate compartment of T helper cells, ILCs also
respond to IL-23 stimulation, and the activation of STAT3
was crucial to the IL-22 production of ILC3s [22]. However,
it is unknown whether STAT3 involves in ILC1-to-ILC3
transdiﬀerentiation as IL-23 is the driving cytokine for this
plasticity [15]. We have observed diﬀerential frequency of
Lineage−CRTH2−CD45+NKp44−CD117−CD127+ILC subset
in the inﬂamed terminal ileum of CD patients [13], suggest-
ing there was a dysregulated ILC plasticity in CD patients.
Herein, we evaluated pSTAT3 levels in ILC subsets in
response to IL-23 stimulation using PBMCs from healthy
donor, and we also desired to investigate whether the carriage
of STAT3 rs744166 “A” allele correlates with the altered acti-
vation level of STAT3 in ILCs. As the result, the NCR-ILC3s
(Lin-CD45+CD56-CD127+CRTH2-CD117+NKp44- cells)
responded rapidly to IL-23 stimulation (Figure 4(a)), and
these cells are more progenitor-like cells which are able to
diﬀerentiate to NCR+ILC3s [29]. We then examined the
phosphorylation level of STAT3 following IL-23 in each
ILC subset (Figure 4(b)). To our surprise, the pSTAT3 signal
was also detected in the Lin-CD45+CD56+CD127+-
CRTH2-CD117-NKp44- ILC1s, which were reported accu-
mulated in the inﬂamed ileum of CD patients [13]. This
result suggested that the activation of STAT3 signaling
may be the ﬁrst step of a signaling cascade for ILC1-to-
ILC3 plasticity and implied that STAT3 potentially has a
regulatory role for ILC1 functioning. Furthermore, we
eager to investigate whether the STAT3 genotypic variant
has impact on cellular STAT3 activation in ILCs in
response to IL-23. Here, we used PBMCs from donors
with A/A and G/G genotypes to evaluate the potential
eﬀect of STAT3 “A” risk allele carriage on the phosphory-
lation of STAT3 in ILCs. Notably, the result revealed that
donors carrying STAT3 rs744166 “A” risk allele exhibited a
higher basal level of STAT3 tyrosine phosphorylation as
well as an increased IL-23-stimulated pSTAT3 level in
Lin-CD45+CD56+CD127+CRTH2- ILCs (Figure 4(c), A:
A/A donor; B: G/G donor). By examination of pSTAT3
after 15 mins and 2 hrs of IL-23 stimulation, we illustrated
that there was no delayed dephosphorylation of STAT3 in
ILCs. In addition, the carriage of “A” allele did not impact
the dephosphorylation of STAT3.
4. Discussion
Despite the introduction of numerous biological agents,
including anti-TNFs, anti-integrin blockers, and more
recently, anti-IL12/23 drugs, for Crohn’s disease patients in
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Figure 3: Increased activation of STAT3 signaling in the inﬂamed ileum of Crohn’s disease patients. (a) Representative images of pSTAT3-
Y705 IHC staining on unaﬀected (n = 6) and inﬂamed ileum of CD patients (n = 10). pSTAT3+ cells were shown as brown dots. Images were
obtained under 20x magniﬁcation. Scale bar = 50 μm. (b) Statistical analysis of pSTAT3-Y705+ cells per HPF in unaﬀected and inﬂamed ileum
of CD patients. Unpaired Mann-Whitney t test was performed, α = 0 05.
6 Journal of Immunology Research
0 0
97.5 2.49
1.27 1.27
64.9 32.6
Lin–CD45+CD56–CD127+CRTH2–
CD117
N
Kp
44
 
(a)
pSTAT3 pSTAT3
NKp44−CD117−ILC1s NKp44−CD117+ILC3s
Unstained control
With IL-23
Without IL-23
0.93
70.1
10.2
0.93
70.0
25.9
(b)
65.2%
3.7%
46.4%
Stimulated with
IL-23 (15 mins) 
Stimulated with
IL-23 (2 hrs) 
Unstimulated
A/A
(A) (B)
pSTAT3
43.8%
3.1%
14.5%
Stimulated with
IL-23 (15 mins) 
Stimulated with
IL-23 (2 hrs) 
Unstimulated
G/G
pSTAT3
(c)
Figure 4: Activation of STAT3 signaling in innate lymphoid cells in response to IL-23 stimulation. (a) PBMCs from healthy donor were
stimulated by 20 ng/ml of IL-23 for 15 minutes. After gating Lin-CD45+CD127+CRTH2- cells, the ILC population was further gated based
on CD117 and NKp44 expression. The CD117+NKp44- ILC3 population (NCR-ILC3 phenotype) was induced by IL-23 stimulation. (b)
IL-23 activated STAT3 signaling in both the CD117-NKp44- ILC1 and CD117+NKp44- ILC3 subsets. (c) After gating
Lin-CD45+CD56+CD127+CRTH2- ILCs, the tyrosine phosphorylation level of STAT3 was evaluated in ILCs. Donor with A/A genotype
was shown in (A), and donor with G/G genotype was demonstrated in (B). The pSTAT3 level after 15 mins or 2 hrs stimulation of IL-23
indicated there was no delayed dephosphorylation in donors, suggesting risky allele “A” carriage does not aﬀect the dephosphorylation of
STAT3 in ILCs.
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remission, relapse rates at one, two, ﬁve, and ten years are
estimated at 20%, 40%, 67%, and 76%, respectively [30].
Therefore, a better understanding of CD pathogenesis is
needed in order to select more speciﬁc and eﬀective treat-
ment regimens. There are several newly approved small mol-
ecule inhibitors targeting JAK-STAT signaling; however, the
responsiveness varies by individual [31]. This study was
mainly focused on investigating the role of STAT3 in the
pathogenesis and progression of Crohn’s disease. We
positively correlated the prevalence of the STAT3 rs744166
risky allele “A” with disease severity in terms of surgery num-
bers (Figure 1). In addition, we observed an increased level of
stat3 mRNA, STAT3-related gene expression, as well as acti-
vation of STAT3 signaling (phosphorylated STAT3) in
inﬂamed ileum tissues of CD patients compared to unaf-
fected ileum (Figures 2 and 3). To investigate STAT3
activity in the innate lymphoid cells of particular interest,
we then speciﬁcally examined pSTAT3 in each of the
ILC subsets in response to IL-23 stimulation (Figure 4).
Notably, we found that STAT3 signaling was not only
activated in the NCR-ILC3 subset but also activated in
Lin-CD45+CRTH2-CD127+CD117-NKp44- cells. Moreover,
we illustrated the carriage of STAT3 genotypic variant
results in an increased basal and IL-23-stimulated STAT3
tyrosine phosphorylation, but it does not aﬀect the
dephosphorylation of STAT3 in ILCs.
Previous studies have focused largely on the role of
adaptive immunity and how it drives the pathogenesis as well
as progression of Crohn’s disease. The research on innate
immune responses have been continuously expanded over
the past two decades [32]. As the important tissue-resident
guardian, innate lymphoid cell has been investigated in both
steady state and diseased state, suggesting the important role
of ILCs in mucosal immunity [33]. Speciﬁcally in Crohn’s
disease patients, our previously published study showed that
the accumulation of IFN-γ-producing Lin-CD45+-
CRTH2-CD127+CD117-NKp44- cells in the inﬂamed termi-
nal ileum of CD patients correlates with disease severity
[13]. However, the paradox we have observed is an increased
STAT3 activity along with decreased ILC3 numbers in the
inﬂamed tissues of CD patients. Bernink et al. not only
proposed that IL-23 triggered ILC1-to-ILC3 transdiﬀeren-
tiation but also pointed out that sustained exposure of
IL-23 was able to promote the reverse conversion [15].
Other groups also pointed out that IL-23 responsive ILC3s
induced pathogenesis of neonatal intestinal inﬂammation
[34]. Additionally, it has been shown that STAT3
phosphorylation in ILC3s was suppressed by the presence
of Treg and Th17 cells [35]. In this study, we revealed that
the STAT3 genotypic variant rs744166 risk allele “A” was
associated with increased basal and IL-23 triggered the
pSTAT3 level in ILCs, but there was no impact on the
dephosphorylation of STAT3 in those genetically susceptible
individuals. Taken together, we suggested that investigation
of STAT3 signaling in a cell-speciﬁc manner is needed for
future researches. IL-23-induced activation of STAT3
signaling in CD117-NKp44- ILC subset suggested that STAT3
plays a role in the initiation of ILC plasticity and also poten-
tially involves in regulating Lin-CD45+CRTH2-CD127+-
CD117-NKp44- ILC1 function. More in depth investigation
on exact gene regulation of STAT3 in ILCs is necessary to fur-
ther explore the exact molecular mechanism of ILC plasticity
and heterogeneity property.
5. Conclusion
Overall, this study illustrated that increased STAT3 activity
was associated with the pathogenesis and progression of
Crohn’s disease. Particularly, activated STAT3 signaling in
IL-23 responsive ILCs may lead to the chronic relapse of
CD. Notably, individuals carrying STAT3 rs744166 “A” risk
allele exhibited increased basal and IL-23-stimulated STAT3
tyrosine phosphorylation in the peripheral ILCs. The results
provide a novel concept of a potential mechanism of ILC
plasticity and also contribute to potential mechanistic strate-
gies for use in personalized medicine in the treatment of
Crohn’s disease patients.
Data Availability
The genotyping, clinical outcomes of patients, and ﬂow
cytometry data used to support the ﬁndings of this study
are available from the corresponding author upon request.
Conflicts of Interest
The authors have no conﬂicts of interest regarding the publi-
cation of this paper.
Acknowledgments
This study was approved by the University of Florida Institu-
tional Review Board.We would like to thank Dr. Iqbal and Dr.
Tan for consenting patients and CTSI Biorepository for pro-
viding human surgical intestinal tissues. We also would like
to thank Dr. Andria Doty, the director of ICBR Cytometry
Core at the UF, for ﬂow cytometry training and troubleshoot-
ing. Moreover, we appreciated the help from the Molecular
Pathology Core at the UF for processing FFPE tissue blocks
and IHC staining. Furthermore, we would like to thank Dr.
Xinyue Liu for statistical analysis consultation. This work
was supported by the Gatorade Trust through funds distrib-
uted by the University of Florida, Department of Medicine.
This work was also supported by the American Gastroentero-
logical Association (AGA) Research Foundation’s Pﬁzer Pilot
Research Award in Inﬂammatory Bowel Disease.
Supplementary Materials
Supplementary 1. Supplementary Table 1: clinical character-
istics of enrolled Crohn’s disease patients.
Supplementary 2. Supplementary Table 2: list of human
immune response genes.
Supplementary 3. Supplementary Table 3: quantitative
expression levels of human immune response genes.
Supplementary 4. Supplementary Figure 1: RT-PCR of stat3
mRNA level in PBMCs from donor and Crohn’s disease
patients.
8 Journal of Immunology Research
Supplementary 5. Supplementary Figure 2: positive and
negative controls of pSTAT3-Y705 IHC staining.
Supplementary 6. Supplementary Figure 3: gating strategy of
ILC subsets using healthy donor PBMCs.
References
[1] M. F. Neurath, “Current and emerging therapeutic targets for
IBD,” Nature Reviews Gastroenterology & Hepatology,
vol. 14, no. 5, pp. 269–278, 2017.
[2] Y. Z. Zhang and Y. Y. Li, “Inﬂammatory bowel disease:
pathogenesis,” World Journal of Gastroenterology, vol. 20,
no. 1, pp. 91–99, 2014.
[3] R. Boyapati, J. Satsangi, and G. T. Ho, “Pathogenesis of
Crohn’s disease,” F1000Prime Reports, vol. 7, 2015.
[4] R. B. Sartor, “Mechanisms of disease: pathogenesis of Crohn’s
disease and ulcerative colitis,” Nature Clinical Practice Gastro-
enterology & Hepatology, vol. 3, no. 7, pp. 390–407, 2006.
[5] Y. Huang and Z. Chen, “Inﬂammatory bowel disease related
innate immunity and adaptive immunity,” American Journal
of Translational Research, vol. 8, no. 6, pp. 2490–2497, 2016.
[6] A. Geremia, P. Biancheri, P. Allan, G. R. Corazza, and A. Di
Sabatino, “Innate and adaptive immunity in inﬂammatory
bowel disease,” Autoimmunity Reviews, vol. 13, no. 1, pp. 3–
10, 2014.
[7] C. Dai, M. Jiang, and M.-J. Sun, “Innate immunity and adap-
tive immunity in Crohn’s disease,” Annals of Translational
Medicine, vol. 3, no. 3, pp. 34–34, 2015.
[8] C. S. N. Klose and D. Artis, “Innate lymphoid cells as regula-
tors of immunity, inﬂammation and tissue homeostasis,”
Nature Immunology, vol. 17, no. 7, pp. 765–774, 2016.
[9] E. Vivier, D. Artis, M. Colonna et al., “Innate lymphoid cells:
10 years on,” Cell, vol. 174, no. 5, pp. 1054–1066, 2018.
[10] G. F. Sonnenberg and D. Artis, “Innate lymphoid cells in the
initiation, regulation and resolution of inﬂammation,” Nature
Medicine, vol. 21, no. 7, pp. 698–708, 2015.
[11] A. Diefenbach, “Innate lymphoid cells in the defense against
infections,” European Journal of Microbiology & Immunology,
vol. 3, no. 3, pp. 143–151, 2013.
[12] M. Colonna, “Innate lymphoid cells: diversity, plasticity, and
unique functions in immunity,” Immunity, vol. 48, no. 6,
pp. 1104–1117, 2018.
[13] J. Li, A. L. Doty, A. Iqbal, and S. C. Glover, “The diﬀerential
frequency of Lineage(-)CRTH2(-)CD45(+)NKp44(-)CD117(-
)CD127(+)ILC subset in the inﬂamed terminal ileum of
patients with Crohn’s disease,” Cellular Immunology,
vol. 304-305, pp. 63–68, 2016.
[14] M. Forkel and J. Mjosberg, “Dysregulation of group 3 innate
lymphoid cells in the pathogenesis of inﬂammatory bowel
disease,” Current Allergy and Asthma Reports, vol. 16, no. 10,
p. 73, 2016.
[15] J. H. Bernink, L. Krabbendam, K. Germar et al., “Interleukin-
12 and -23 control plasticity of CD127(+) group 1 and group
3 innate lymphoid cells in the intestinal lamina propria,”
Immunity, vol. 43, no. 1, pp. 146–160, 2015.
[16] A. Geremia and C. V. Arancibia-Cárcamo, “Innate lymphoid
cells in intestinal inﬂammation,” Frontiers in Immunology,
vol. 8, pp. 1296–1296, 2017.
[17] UK IBD Genetics Consortium, J. C. Lee, D. Biasci et al.,
“Genome-wide association study identiﬁes distinct genetic
contributions to prognosis and susceptibility in Crohn’s dis-
ease,” Nature Genetics, vol. 49, no. 2, pp. 262–268, 2017.
[18] J. Zhang, J. Wu, X. Peng, J. Song, J. Wang, and W. Dong,
“Associations between STAT3 rs744166 polymorphisms
and susceptibility to ulcerative colitis and Crohn’s disease:
a meta-analysis,” PLoS One, vol. 9, no. 10, article e109625,
2014.
[19] T. A.Willson, B. R. Kuhn, I. Jurickova et al., “STAT3 genotypic
variation and cellular STAT3 activation and colon leukocyte
recruitment in pediatric Crohn disease,” Journal of Pediatric
Gastroenterology and Nutrition, vol. 55, no. 1, pp. 32–43,
2012.
[20] K. Sugimoto, “Role of STAT3 in inﬂammatory bowel disease,”
World Journal of Gastroenterology, vol. 14, no. 33, pp. 5110–
5114, 2008.
[21] M. Ciofani, A. Madar, C. Galan et al., “A validated regulatory
network for Th17 cell speciﬁcation,” Cell, vol. 151, no. 2,
pp. 289–303, 2012.
[22] X. Guo, J. Qiu, T. Tu et al., “Induction of innate lymphoid cell-
derived interleukin-22 by the transcription factor STAT3
mediates protection against intestinal infection,” Immunity,
vol. 40, no. 1, pp. 25–39, 2014.
[23] L. C. Rankin, M. J. H. Girard-Madoux, C. Seillet et al., “Com-
plementarity and redundancy of IL-22-producing innate lym-
phoid cells,” Nature Immunology, vol. 17, no. 2, pp. 179–186,
2016.
[24] O. . I. Koues, P. . L. Collins, M. Cella et al., “Distinct gene reg-
ulatory pathways for human innate versus adaptive lymphoid
cells,” Cell, vol. 165, no. 5, pp. 1134–1146, 2016.
[25] N. Seraﬁni, C. A. J. Vosshenrich, and J. P. Di Santo, “Tran-
scriptional regulation of innate lymphoid cell fate,” Nature
Reviews Immunology, vol. 15, no. 7, pp. 415–428, 2015.
[26] L. R. Ferguson, D. Y. Han, A. G. Fraser et al., “Genetic factors
in chronic inﬂammation: single nucleotide polymorphisms in
the STAT-JAK pathway, susceptibility to DNA damage and
Crohn’s disease in a New Zealand population,” Mutation
Research/Fundamental and Molecular Mechanisms of Muta-
genesis, vol. 690, no. 1-2, pp. 108–115, 2010.
[27] G. Can, A. Tezel, H. Gurkan et al., “Investigation of IL23R,
JAK2, and STAT3 gene polymorphisms and gene-gene inter-
actions in Crohn’s disease and ulcerative colitis in a Turkish
population,” The Turkish Journal of Gastroenterology, vol. 27,
no. 6, pp. 525–536, 2016.
[28] G. Pickert, C. Neufert, M. Leppkes et al., “STAT3 links IL-22
signaling in intestinal epithelial cells to mucosal wound heal-
ing,” The Journal of Experimental Medicine, vol. 206, no. 7,
pp. 1465–1472, 2009.
[29] S. A. van de Pavert and E. Vivier, “Diﬀerentiation and function
of group 3 innate lymphoid cells, from embryo to adult,” Inter-
national Immunology, vol. 28, no. 1, pp. dxv052–dxv042, 2015.
[30] A. Lapidus, O. Bernell, G. Hellers, and R. Lofberg, “Clinical
course of colorectal Crohn’s disease: a 35-year follow-up study
of 507 patients,” Gastroenterology, vol. 114, no. 6, pp. 1151–
1160, 1998.
[31] L. C. S. De Vries, M. E. Wildenberg, W. J. De Jonge, and G. R.
D’Haens, “The future of Janus kinase inhibitors in inﬂamma-
tory bowel disease,” Journal of Crohn's and Colitis, vol. 11,
no. 7, pp. 885–893, 2017.
[32] N. Li and R.-H. Shi, “Updated review on immune factors in
pathogenesis of Crohn’s disease,” World Journal of Gastroen-
terology, vol. 24, no. 1, pp. 15–22, 2018.
9Journal of Immunology Research
[33] A. Ignacio, C. N. S. Breda, and N. O. S. Camara, “Innate
lymphoid cells in tissue homeostasis and diseases,” World
Journal of Hepatology, vol. 9, no. 23, pp. 979–989, 2017.
[34] L. Chen, Z. He, E. Slinger et al., “IL-23 activates innate
lymphoid cells to promote neonatal intestinal pathology,”
Mucosal Immunology, vol. 8, no. 2, pp. 390–402, 2015.
[35] K. Mao, A. P. Baptista, S. Tamoutounour et al., “Innate and
adaptive lymphocytes sequentially shape the gut microbiota
and lipid metabolism,” Nature, vol. 554, no. 7691, pp. 255–
259, 2018.
10 Journal of Immunology Research
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
